Truist Maintains Buy Rating on Procept BioRobotics (PRCT) Amid MedTech Sector Rotation

Procept BioRobotics Corporation (NASDAQ:PRCT) is one of the best up and coming stocks to buy according to Wall Street. On December 18, Truist analyst Richard Newitter lowered the firm’s price target on Procept BioRobotics to $47 from $50 while keeping a Buy rating on the shares as part of a 2026 MedTech sector preview. Although the firm is more optimistic about the industry due to attractive valuations, it cautioned that MedTech might act as a source of funds rather than a primary destination for new capital. Truist expressed a preference for companies with specific catalysts capable of driving long-term revenue growth and those suffering from unpopular short-term market narratives.

On December 12, the company was initiated by UBS analyst Danielle Antalffy with a Buy rating and $62 price target. Consultations with key opinion leaders have supported the firm’s confidence in the company’s utilization growth through 2026 and 2027. The firm believes that the market is currently overlooking several core strengths: Procept’s initiatives to increase usage across its current hardware, the vast potential for new system placements in untapped markets, and the margin growth expected from a more profitable product mix.

Truist Maintains Buy Rating on Procept BioRobotics (PRCT) Amid MedTech Sector Rotation

Earlier on December 8, Bank of America also downgraded Procept BioRobotics Corporation (NASDAQ:PRCT) to Neutral from Buy with a price target of $38, which was brought down from $55. While Procept’s aquablation tech holds significant market potential for treating benign prostatic hyperplasia, BofA warned investors that slowing utilization growth is a growing concern. Although the company is implementing changes to boost usage, these adjustments may cause short-term operational friction. The firm concluded that the simultaneous slowdown in both system sales and procedure volume makes it difficult to feel confident about the stock’s potential for near-term growth.

Procept BioRobotics Corporation (NASDAQ:PRCT) is a surgical robotics company that develops transformative solutions in urology in the US and internationally.

While we acknowledge the potential of PRCT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PRCT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.